Abstract
The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
| Original language | English |
|---|---|
| Patent number | US2013280209 |
| IPC | A61K 39/ 395 A I |
| Priority date | 15/04/13 |
| State | Published - 24 Oct 2013 |
